Kaken Pharmaceutical Co Ltd represents core values of innovation, ethics, and excellence. With a strong commitment to improving global health, the company focuses on developing and providing high-quality pharmaceutical products. Kaken Pharmaceutical Co Ltd fosters a corporate philosophy based on integrity, responsibility, and respect for stakeholders, including patients, healthcare professionals, and the community. By adhering to strict regulatory standards and promoting research and development activities, Kaken Pharmaceutical Co Ltd strives to contribute to society and enhance the well-being of people worldwide. This Japanese company's dedication to advancing healthcare solutions and its unwavering commitment to its core values make it a trusted leader in the pharmaceutical industry.

Kaken Pharmaceutical Co Ltd is primarily present in Japan.

Kaken Pharmaceutical Co Ltd has achieved several significant milestones throughout its history. One of the notable accomplishments includes the successful development and launch of innovative pharmaceutical products that have greatly contributed to the healthcare industry. The company's commitment to research and development has led to breakthroughs in various therapeutic areas. Kaken Pharmaceutical Co Ltd has also established strategic partnerships and collaborations with renowned medical institutions and organizations, enabling the company to expand its global presence and reach more patients in need. With a strong focus on innovation and continuous growth, Kaken Pharmaceutical Co Ltd continues to make significant strides towards improving the lives of individuals worldwide.

Kaken Pharmaceutical Co Ltd is a renowned company in the pharmaceutical industry. Founded in 1949, it has a rich history and a strong background in developing and manufacturing high-quality healthcare products. Over the years, Kaken Pharmaceutical Co Ltd has established itself as a leading player, specializing in therapeutic solutions for dermatology and musculoskeletal disorders. With a focus on research and innovation, they have consistently introduced groundbreaking treatments that cater to the evolving needs of patients worldwide. With their commitment to excellence and a diverse portfolio of products, Kaken Pharmaceutical Co Ltd continues to be a trusted name in the pharmaceutical sector.

The main competitors of Kaken Pharmaceutical Co Ltd in the market include other pharmaceutical companies such as Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, Astellas Pharma Inc, and Eisai Co., Ltd.

Kaken Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

Kaken Pharmaceutical Co Ltd operates under a business model that focuses on the research, development, manufacturing, and marketing of pharmaceutical products. As a leading company in the Japanese pharmaceutical industry, Kaken Pharmaceutical aims to improve the quality of life for patients by providing innovative medical solutions and therapies. By leveraging its expertise in drug discovery and advanced technologies, Kaken Pharmaceutical strives to address various medical needs and contribute to the betterment of society. With its extensive product portfolio and commitment to research and development, Kaken Pharmaceutical Co Ltd aims to uphold its position as a trusted provider of cutting-edge pharmaceuticals.

The Kaken Pharmaceutical Co P/E ratio is 10.37.

The Kaken Pharmaceutical Co P/S ratio is 1.54.

The Quality Investing for Kaken Pharmaceutical Co is 4/10.

The Kaken Pharmaceutical Co revenue is 94.04 B JPY.

The Kaken Pharmaceutical Co profit is 13.95 B JPY.

Kaken Pharmaceutical Co Ltd is a Japanese company specialized in the development, manufacture, and marketing of pharmaceuticals and medical devices. The company was founded in 1949 and is headquartered in Tokyo, Japan. It is divided into two main business segments: Pharma and Medical Devices. In the Pharma sector, the company produces and distributes innovative drugs used in various therapy areas such as Dermatology, Infectious Diseases, Pediatrics, Hematology, and Oncology. Kaken's product range includes topical antifungals and topical steroids, among others. One of the core competencies of the company is the treatment of fungal infections of the skin, nails, and mucous membranes. The Medical Devices division of Kaken Pharmaceutical Co Ltd focuses on the development and manufacture of medical devices. This includes artificial joints, surgical instruments, probes, catheters, stents, and hearing aids, among others. The devices are characterized by high precision, long durability, and good compatibility. The company has numerous manufacturing facilities in Japan and regional branches in Europe, Asia, and North America. Distribution is carried out both in Japan and internationally through a network of subsidiaries and local distribution partners. Kaken Pharmaceutical Co Ltd also conducts intensive research and development efforts to develop new products. The company invests in various research fields to ensure that it can offer customers high-quality pharmaceuticals and medical devices that meet the high demands of patients. This also includes biological therapeutics, vaccines, and therapeutics for rare diseases. In addition to product development and manufacturing, the development of new business models is also an important topic at Kaken Pharmaceutical Co Ltd. The company aims to establish partnerships and alliances with other companies in the pharmaceutical industry in Japan and internationally to strengthen its global presence and access to new markets. In terms of the future, it can be assumed that Kaken Pharmaceutical Co Ltd will continue to expand its leadership position in the Japanese pharma and MedTech industry. New product developments, partnerships, and investments in research and development are the key pillars of the company to continue offering high-quality products to its customers in the future.

Kaken Pharmaceutical Co pays a dividend of 150 JPY distributed over 2 payouts per year.

Kaken Pharmaceutical Co pays out a dividend 2 times a year.

The ISIN of Kaken Pharmaceutical Co is JP3207000005.

The ticker of Kaken Pharmaceutical Co is 4521.T.

Over the past 12 months, Kaken Pharmaceutical Co paid a dividend of 75 JPY . This corresponds to a dividend yield of about 1.98 %. For the coming 12 months, Kaken Pharmaceutical Co is expected to pay a dividend of 77.7 JPY.

The current dividend yield of Kaken Pharmaceutical Co is 1.98 %.

Kaken Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

Kaken Pharmaceutical Co paid dividends every year for the past 22 years.

For the upcoming 12 months, dividends amounting to 77.7 JPY are expected. This corresponds to a dividend yield of 2.05 %.

Kaken Pharmaceutical Co is assigned to the 'Health' sector.

To receive the latest dividend of Kaken Pharmaceutical Co from 6/1/2025 amounting to 75 JPY, you needed to have the stock in your portfolio before the ex-date on 3/28/2025.

The last dividend was paid out on 6/1/2025.

In the year 2024, Kaken Pharmaceutical Co distributed 115 JPY as dividends.

The dividends of Kaken Pharmaceutical Co are distributed in JPY.